Clostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis
- 264 Downloads
The prevalence of Clostridium difficile infection is rapidly increasing worldwide, but prevalence is difficult to estimate in developing countries where awareness, diagnostic resources, and surveillance protocols are limited. As diarrhea is the hallmark symptom, we conducted a systematic review and meta-analysis to determine the prevalence and incidence of C. difficile infection in patients in these regions who presented with diarrhea.
We conducted a systematic literature search of MEDLINE/PubMed, Scopus, and Latin-American and Caribbean Health Sciences Literature databases to identify and analyze data from recent studies providing prevalence or incidence rates of C. difficile-associated diarrhea in developing countries within four regions: Africa–Middle East, developing Asia, Latin America, and China. Our objectives were to determine the current prevalence and incidence density rates of first episodes of C. difficile-associated diarrhea in developing countries.
Within the regions included in our analysis, prevalence of C. difficile infection in patients with diarrhea was 15% (95% CI 13–17%) (including community and hospitalized patients), with no significant difference across regions. The incidence of C. difficile infection in 17 studies including this information was 8.5 per 10,000 patient-days (95% CI 5.83–12.46). Prevalence was significantly higher in hospitalized patients versus community patients (p = 0.0227).
Our prevalence estimate of 15% is concerning; however, low awareness and inconsistent diagnostic and surveillance protocols suggest this is markedly underestimated. Enhanced awareness and management of C. difficile infection in patients with diarrhea, along with improvements in infection control and surveillance practices, should be implemented to reduce prevalence of C. difficile-associated diarrhea in developing countries.
KeywordsClostridium difficile infection C. difficile-associated diarrhea Developing countries Nosocomial diarrhea
The incidence of Clostridium difficile infection has greatly increased in recent years as new strains have emerged and antimicrobial resistance has increased (i.e., hypervirulent C. difficile ribotype 027 and ribotype 078) [1, 2, 3, 4, 5, 6, 7]. Precise global epidemiologic data are difficult to obtain, due to continually changing prevalence data and variations in surveillance practices. One recent US analysis estimated 453,000 C. difficile cases, 29,000 deaths, and a healthcare-related incidence of 92.8 per 100,000 persons . European epidemiological data indicate wide variation in reported incidence of C difficile infection . The survey of hospitalized patients in 97 institutions reported a weighted mean incidence of 4.1 per 10,000 patient-days, with individual country rates ranging from 0 to 36.3. In Latin America, Asia, and Africa, recent and comprehensive epidemiologic data on C. difficile infection are limited [1, 10].
Commonly associated with antibiotic use [4, 11, 12, 13], C. difficile was previously regarded primarily as a nosocomial infection [11, 14]; however, community-acquired C. difficile has now emerged as a significant public health threat [3, 8, 11, 14, 15, 16]. The epidemiology of community-acquired infection is not well understood . While both nosocomial and community-acquired infection can be severe and even fatal, patients with community-acquired infection often do not have the risk factors (e.g., age ≥ 65, treatment with antibiotics, certain comorbidities) known to be associated with nosocomial infection [11, 13, 14, 17, 18].
Clostridium difficile-associated diarrhea (CDAD) is the hallmark symptom of clinical infection and can range in severity from mild diarrhea to fulminant colitis [12, 15]. C. difficile is recognized as a leading cause of healthcare-associated diarrhea [11, 19] and as the main contributing factor in gastroenteritis-associated hospitalizations and deaths [12, 20]. Mortality associated with CDAD is high, particularly in patients ≥ 65 years with comorbid conditions, severe disease, or hypervirulent strains .
In developing countries, surveillance data on C. difficile infection are not readily available, likely due to limitations in awareness, laboratory capacity and capabilities, and surveillance systems [22, 23, 24]. A recent review of the burden of C. difficile infection in developing countries noted that patients with diarrhea are not routinely tested for this pathogen, and, when tested, it is very often with enzyme immunoassay (EIA) rather than stool culture . Clinical Practice Guidelines for C. difficile note that EIA is less sensitive than stool culture and is therefore an inferior alternative [11, 19]. As C. difficile has become resistant to many antimicrobials [1, 10], prevention of infection through the implentation of infection control and hospital epidemiology programs must be a priority .. With a better understanding of the epidemiologic trends related to CDAD, enhanced approaches to the prevention and control of C. difficile infection and associated diarrhea may be achieved. The primary objective of this systematic review and meta-analysis was to determine the current prevalence of CDAD first episodes (nosocomial or community-acquired) in developing countries. The secondary objective was determination of hospital incidence rates (cases per 10,000 patient-days) within the same case parameters.
Search Strategy and Selection Criteria
Developing countries included in this analysis
Africa–Middle East (AfME)
United Arab Emirates
Developing Asia (ASIA)
Latin America (LATAM)
To quantify the current burden, our search was limited to publications from January 2000 to December 2017. No language restrictions were applied; however, we required that at least the abstract of a paper be available in English in order for it to be included in our full analysis. Details of our search strategy, including specific search terms and strings, are described in the Supplementary Materials.
To capture both nosocomial and community-acquired CDAD, the selected studies included cases in hospitalized patients and/or outpatients. We also considered factors such as whether the cases occurred during a known outbreak period, and age groups covered by the studies (adult, pediatric, or both). Clinical data were extracted from each study for analysis.
Review articles and other publications citing data from more than one study were not included; however, their citations were used to identify individual studies that had not already been identified in the literature search. Studies were included if they provided prevalence (proportion) data and/or estimated incidence density rates (cases per 10,000 patient-days). Studies were excluded if they included only recurrent or asymptomatic cases, if there was evidence of explicit selection bias (e.g., unclear denominator), or if they considered rates of admissions and/or discharges (unless they also considered patient-days).
The decision for inclusion of each study was made by Drs. Fernández and Correa, functioning as independent reviewers and screening the studies by title and abstract. Resolution of any differences was determined by Dr. Curcio.
Assessment of Study Quality
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) model  in structuring our literature analysis. In the context of our meta-analysis, the main source of quality variation results from the biases introduced during the selection of patients (e.g., when the denominator is smaller than the sum of all symptomatic cases). Because the presence of this type of selection bias has been used as an exclusion criterion in our analysis, it is assumed that the studies we selected are relatively homogeneous in quality.
For the primary analysis of prevalence of CDAD, studies that provided information on the proportion of occurrence were included. The secondary objective of incidence density rate (cases per 10,000 patient-days) was analyzed on the studies providing incidence data. A subanalysis was also carried out on the prevalence data, stratifying studies across the four specified geographic regions (Table 1). An overall effect-size analysis was also performed using the incidence density rate data.
The potential for publication bias was evaluated using a funnel plot as a graphical method to determine the trials’ effect estimates of effect size against the measure of precision for all included studies . We also utilized the Egger linear regression test for funnel plot asymmetry, which may be indicative of bias in meta-analyses .
A meta-regression analysis, which is generally performed to identify relationships between dependent and independent variables across studies and/or subgroups , was conducted relevant to the route of C. difficile acquisition, geographic regions, occurrence during known outbreaks, and age groups. For those covariates demonstrating statistical significance in the meta-regression analysis, a subanalysis was conducted.
Because a proportion as an effect to be measured raises particular concerns, a funnel plot was used for the meta-analysis to stabilize variances across studies prior to pooling the data [30, 31]. In contrast, the logarithmic transformation of the variable was used to analyze the incidence density values . The random effects model was utilized for the global effect size when significant heterogeneity across studies was shown.
For the statistical analysis of the values expressed as a proportion, the Metaprop package in R software (v.3.4.2) was used. For the analysis of the values expressed as incidence, the implementation of the transformation suggested by Stijnen et al.  was used from the Metafor package of the same R software.
Compliance with Ethics Compliance
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
Publication Bias Analysis
Summary of meta-regression analysis
Route of acquisition (ref = Both)
− 0.2088 to 0.0888
0.0165 to 0.2196
Outbreak (ref = No)
− 0.2860 to 0.2329
Age group (ref = Adult)
− 0.1280 to 0.0355
− 0.2267 to 0.0603
− 0.4719 to 0.0589
Region (ref = AfME)
− 0.1184 to 0.0494
− 0.0508 to 0.1543
− 0.0367 to 0.1589
In this meta-analysis of CDAD in developing countries, we found 15% of diarrhea cases to be attributable to C. difficile infection (including community and hospitalized patients). The proportions were highest in LATAM and China, but there was no significant difference across regions. This study outcome was specific to determining the cause of diarrhea in patients presenting with this symptom. Due to inconsistencies in study designs, comparisons to other parts of the world are not always easily drawn, and lower prevalences of C. difficile infection in patients with diarrhea have been observed (range 7.4–12.7%). For example, in a prospective analysis of 4659 fecal samples from inpatients in the United Kingdom with suspected antibiotic-associated diarrhea, C. difficile was determined to be the causative pathogen in 12.7% of cultures . A Berlin study that included analysis of 693 cultures from inpatients with antibiotic-associated diarrhea detected C. difficile in 11.4% of samples . A smaller study conducted at a major hospital in Houston, Texas, USA, found C. difficile to be the causative pathogen in 7.4% of 81 inpatients experiencing diarrhea . Based on these limited data, the prevalence of CDAD is higher in the developing countries included in our study.
Similarly, the incidence of C. difficile infection among patients with diarrhea in developing countries, which we determined to be 8.5 per 10,000 patient-days (95% CI 5.56–11.79), is not easily compared to incidence rates in more developed regions such as the US and Europe. However, this undoubtedly low incidence rate is approximately twice that reported in Europe. The hospital-based European survey noted above resulted in a weighted incidence of 4.1 per 10,000 patient-days, with considerable variation in individual country rates . It was noted that factors such as diagnostic procedures and capabilities were inconsistent, making it difficult to compare epidemiologic trends across countries within this survey. US data from the 2011 survey referenced above indicate a mean crude incidence of 9.3 and 4.8 per 10,000 persons for healthcare-associated and community-acquired C. difficile infection, respectively . A report from the US Centers for Disease Control and Prevention estimated the mean crude incidence for C. difficile infection in 2015 to be 14.9 per 10,000 persons (8.3 and 6.6 for healthcare-associated and community-acquired infection, respectively) . While the US rate of 14.9 per 10,000 persons appears to be comparable to that of developing countries in our analysis, we must recognize that we would expect reported rates to be higher in developed regions where C. difficile infection is more proactively assessed and managed.
Although we found no statistically significant differences in prevalence across regions, due to numerous factors related to diagnosis and management, it may be reasonably assumed that prevalence might be underestimated. It has been observed that awareness of C. difficile as a cause of diarrhea is relatively low in developing regions such as Asia and Latin America [22, 123]. For example, a 2015 survey of physicians in Latin American countries reported low-to-moderate knowledge of C. difficile diagnosis and management . Similarly, a survey of physicians in Taiwan found marked differences between internationally accepted treatment guidelines for C. difficile and actual clinical practice . In addition, diagnostic capacity and capabilities in developing countries are generally suboptimal [22, 23, 124, 126]. Thus, CDAD is likely under-recognized and insufficiently managed in these regions.
Our meta-regression analysis found the route of acquisition to be the only prespecified variable to demonstrate a statistically significant difference, with the value of the ratio for CDAD being higher in hospitalized patients than in community patients. Our subanalysis corroborated this finding, showing the prevalence of CDAD to be significantly higher in studies including only hospitalized patients versus those including community patients or both. A number of factors may be contributing to this finding. The risk of hospital-acquired infections such as C. difficile is greater in developing countries, which lack resources for effective infection control programs [127, 128]. Hospitalized patients are more likely to have the recognized risk factors for C. difficile infection, namely advanced age, antibiotic use, and certain comorbidities. Prescribing rates for antibiotics, particularly those strongly associated with C. difficile infection (e.g., cephalosporins, fluoroquinolones), are higher in the developing countries than in other regions .
While the data on healthcare-acquired CDAD are salient, it is important to consider that community acquisition is a relatively new trend that until recently has not been a focus of epidemiologic research. Of the 85 studies included in our analysis that provided prevalence data, only 12 included cases of community-acquired CDAD (7 included both hospital-acquired and community-acquired cases). This under-surveillance is likely masking a higher rate of community-acquired disease in these developing countries. In areas where surveillance is more aggressive, proportions of community-acquired CDAD have been shown to be much higher. In the US, for example, community onset accounted for almost 50% of C. difficile infections in 2010 .
Study limitations include, as previously noted, the potential for significant publication bias related to high variability among the studies selected. Publication bias in meta-analyses is often attributable to the number of included studies being lower than the total number of studies conducted . By closely adhering to the PRISMA model in selecting studies for inclusion , we feel we have minimized this concern. However, the definition of CDAD according to microbial testing may have varied across studies. Inconsistencies in study designs also make it challenging to compare prevalence in developing countries to that in more developed areas, such as the US and Europe. Along those lines, wide variation in diagnostic protocols and surveillance practices would suggest that prevalence and incidence of CDAD are underestimated. In addition, in most of the included studies in our meta-analysis, populations were poorly defined, which might make comparisons unclear.
We found no data related to CDAD in long-term care facilities, which would now be included under the umbrella of nosocomial acquisition. We found only 17 articles with data on incidence rates, which makes that aspect of the analysis underpowered.
Low awareness of CDAD in developing countries and inconsistent surveillance protocols likely cause marked underestimates of prevalence and incidence rates in developing countries. In this meta-analysis, we estimated prevalence of C. difficile infection to be 15% in patients with diarrhea; however, this should be considered the tip of the iceberg in light of limited diagnostic resources and protocols, as well as the low level of awareness, in developing countries. Hospital-acquired CDAD was found to be a greater concern than community-acquired disease, although the latter is undoubtedly trending upward. Heightened awareness of CDAD among healthcare providers; as well as enhancements in diagnostic capabilities, infection control, and surveillance protocols; should be implemented to better manage and prevent C. difficile infection and associated diarrhea in developing countries.
Sponsorship of this study and article processing charges were funded by Pfizer Inc.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Medical Writing and Editorial Assistance
The statistical analysis was conducted by Content Medicine in Buenos Aires, Argentina; funding was provided by Pfizer Inc. Ann L. Davis, MPH, CMPP, an employee of Pfizer Inc, provided writing support for the manuscript under the direction of the authors.
Daniel Curcio is an employee of Pfizer, Inc. and may hold stock in the company. Alejandro Cané is an employee of Pfizer, Inc. and may hold stock in the company. Francisco Andrés Fernández and Jorge Correa have nothing to disclose.
Compliance with Ethics Compliance
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- 2.Centers for Disease Control and Prevention. Vital signs: preventing Clostridium difficile infections. Morb Mortal Wkly Rep. 2012;61(9):157–62.Google Scholar
- 3.To KB, Napolitano LM. Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt). 2014;15(5):490–502.Google Scholar
- 7.Smits WK. Hype or hypervirulence: a reflection on problematic C. difficile strains. Virulence. 2013;4(7):592–6.Google Scholar
- 11.Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedGoogle Scholar
- 12.Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3:CD004610.Google Scholar
- 16.Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 23 Oct 2018.
- 19.McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–94.PubMedGoogle Scholar
- 22.Cheng JW, Xiao M, Kudinha T, et al. The role of glutamate dehydrogenase (GDH) testing assay in the diagnosis of Clostridium difficile infections: a high sensitive screening test and an essential step in the proposed laboratory diagnosis workflow for developing countries like China. PLoS ONE. 2015;10(12):e0144604.PubMedPubMedCentralGoogle Scholar
- 26.Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.Google Scholar
- 30.Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–8.Google Scholar
- 34.Ferreira CE, Nakano V, Durigon EL, Avila-Campos MJ. Prevalence of Clostridium spp. and Clostridium difficile in children with acute diarrhea in Sao Paulo city, Brazil. Mem Inst Oswaldo Cruz. 2003;98(4):451–4.Google Scholar
- 67.Lee YC, Wang JT, Chen AC, Sheng WH, Chang SC, Chen YC. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect. 2012;45(4):287–95.PubMedGoogle Scholar
- 89.Rodríguez-Varón A, Muñoz OM, Pulido-Arenas J, Amado SB, Tobón-Trujillo M. Antibiotic-associated diarrhea: clinical characteristics and the presence of Clostridium difficile. Rev Gastroenterol Mex. 2017;82(2):129–33.Google Scholar
- 92.Costa CL, Mano de Carvalho CB, Gonzalez RH, et al. Molecular epidemiology of Clostridium difficile infection in a Brazilian cancer hospital. Anaerobe. 2017;48:232–6.Google Scholar
- 93.Oñate-Gutiérreza JM, Villegasa MV, Correa A. Prevalencia y factores relacionados con la infección por Clostridium difficile en un centro hospitalario de alta complejidad en Cali (Colombia). Infection. 2016:9–14.Google Scholar
- 96.Senok AC, Aldosari KM, Alowaisheq RA, et al. Detection of Clostridium difficile antigen and toxin in stool specimens: comparison of the C. difficile quik chek complete enzyme immunoassay and GeneXpert C. difficile polymerase chain reaction assay. Saudi J Gastroenterol. 2017;23(4):259–62.Google Scholar
- 97.Rezazadeh Zarandi E, Mansouri S, Nakhaee N, Sarafzadeh F, Iranmanesh Z, Moradi M. Frequency of antibiotic associated diarrhea caused by Clostridium difficile among hospitalized patients in intensive care unit, Kerman, Iran. Gastroenterol Hepatol Bed Bench. 2017;10(3):229–34.PubMedPubMedCentralGoogle Scholar
- 98.Putsathit P, Maneerattanaporn M, Piewngam P, Kiratisin P, Riley TV. Prevalence and molecular epidemiology of Clostridium difficile infection in Thailand. New Microb New Infect. 2017;15:27–32.Google Scholar
- 99.Collins DA, Gasem MH, Habibie TH, et al. Prevalence and molecular epidemiology of Clostridium difficile infection in Indonesia. New Microb New Infect. 2017;18:34–7.Google Scholar
- 102.Jia H, Yang H, Du P, et al. Analysis of toxin and multilocus sequence typing of Clostridium difficile strains isolated from China-Japan Friendship Hospital. Chin J Microbiol Immunol. 2017;37:297–302.Google Scholar
- 103.Yan J, Liang J, Lv T, et al. Epidemiology of Clostridium difficile in a County Level Hospital in China. Jundishapur J Microbiol. 2017;10(6):e14376.Google Scholar
- 106.Kim J, Kang JO, Kim H, et al. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clin Microb Infect. 2013;19(6):521–7.Google Scholar
- 122.Centers for Disease Control and Prevention. 2015 Annual Report for the Emerging Infections Program for Clostridium difficile Infection. Updated 24 July 2017. https://www.cdc.gov/hai/eip/Annual-CDI-Report-2015.html. Accessed 1 Aug 2018.
- 124.Cane A, Curcio D, Quintana A. Physician knowledge of Clostridium difficile: a Latin American survey. Presented at: 26th European Congress of Clinical Microbiology and Infectious Diseases. April 9–12, 2016. Amsterdam, Netherlands.Google Scholar